These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 9422404)

  • 21. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study.
    Sadek S; Medina J; Arias M; Sennesael J; Squifflet JP; Vogt B;
    Transplantation; 2002 Aug; 74(4):511-7. PubMed ID: 12352910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation.
    Ciancio G; Lo Monte A; Buscemi G; Miller J; Burke GW
    Transpl Int; 2000; 13 Suppl 1():S191-4. PubMed ID: 11111994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations.
    Kim YS; Moon JI; Kim SI; Park K
    Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation.
    Lee CM; Scandling JD; Krieger NR; Dafoe DC; Alfrey EJ
    Transplantation; 1997 Nov; 64(9):1288-94. PubMed ID: 9371670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
    Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
    Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of the immunosuppressive protocol after lung transplantation.
    Reichenspurner H; Kur F; Treede H; Meiser BM; Deutsch O; Welz A; Vogelmeier C; Schwaiblmair M; Müller C; Fürst H; Briegel J; Reichart B
    Transplantation; 1999 Jul; 68(1):67-71. PubMed ID: 10428269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of azathioprine and mycophenolate mofetil for the prevention of acute rejection in recipients of pancreas transplantation.
    Oh JM; Wiland AM; Klassen DK; Weidle PJ; Bartlett ST
    J Clin Pharmacol; 2001 Aug; 41(8):861-9. PubMed ID: 11504274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
    Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens.
    Wlodarczyk Z; Walaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradszky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Kalmar KN; Hickey D
    Transpl Int; 2005 Feb; 18(2):157-62. PubMed ID: 15691267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.